^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Published date:
09/20/2020
Excerpt:
...we report the results of a phase I trial in patients with HER2+ solid tumors….with GC/GEJ (n=25); BC (n=16); gynecological cancer (n=6); CRC (n=10); BTC (n=5); UC (n=2); melanoma, pancreatic and salivary duct cancer (n=1 each) were treated with PRS-343....PRS-343 is the first 4-1BB bispecific to demonstrate encouraging evidence of safety and clinical benefit with a correlative PD effect.